Home World News FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients... World News FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 ESMO Breast Cancer Virtual Congress 2021, 5-8 May April 28, 2021 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and... April 2, 2025 Load more HOT NEWS How I’m Working to Erase the Stigma of Lung Cancer: A... Non-pharmacological interventions – are they important to patients with cancer? Thinking outside the chromosome – how ecDNA is challenging conventional thinking Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC...